Kinetic and thermodynamic studies of moxifloxacin hydrolysis in the presence and absence of metal ions in acidic solutions by Hubicka, Urszula et al.
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 70 No.1 pp. 59ñ70, 2013 ISSN 0001-6837
Polish Pharmaceutical Society
Moxifloxacin (1-cyclopropyl-7-[(1S, 6S)-2,8-
diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-4-
oxoquinoline-3-carboxylic acid, monohydrochloride)
is a fourth generation synthetic fluoroquinolone
chemotherapeutic agent (1). It possesses excellent
activities against a variety of different types of Gram-
negative (Streptococcus pneumoniae and Staphylo-
coccus aureus), Gram-positive (Enterobacteriaceae
family, and Pseudomonas aeruginosa) and anaerobic
bacteria (Bacteroides and Clostridium). Its activity
against atypical bacteria of Chlamydia spp.,
Mycoplasma spp., and Legionella spp. genera and
bacilli of genus Mycobacterium is of high value (2ñ5). 
The mechanism of action of moxifloxacin,
similar to other fluoroquinolones, lies in inhibiting
the activity of two bacterial enzymes ñ DNA gyrase
(topoisomerase II) and topoisomerase IV ñ which
regulate spatial arrangement of DNA in bacterial
cells. These proteins can cut both strands of the
nucleic acid and rejoin them. Inhibiting the activity
of those enzymes by formation of irreversible com-
plex drug/enzyme/DNA, disables DNA synthesis
and leads to the bacterial cell death (3, 4).
According to the available literature, high pres-
sure liquid chromatography (HPLC) technique is
mainly used for analysis of moxifloxacin in pharma-
ceutical preparations and biological material (5ñ14).
This technique was used for identification of moxi-
floxacin and its decomposition products (1, 15, 16).
The ligand-exchange liquid chromatography with
the use of a chiral modifier in stationary phase was
used for separation of moxifloxacin and its (R, R)-
isomer (17). 
The LC-MS/MS technique was used for identi-
fication and quantification of moxifloxacin in
human plasma and cerebrospinal fluid (18, 19). 
The TLC method for identification of lome-
floxacin, moxifloxacin and sparfloxacin and their
decomposition products was recommended by
Salem et al. (20). Identification of moxifloxacin was
performed on TLC plates covered with silica gel
with the mobile phase: 0.3 M ammonium acetate
solution ñ conc. ammonia ñ n-propanol (1: 1: 8,
v/v/v). The spots on chromatograms were recorded
densitomerically at λ = 290 nm (20).
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For stress studies with moxifloxacin, Motwani
et al. used the silica gel coated HPTLC plates and
the mobile phase: propanol ñ ethanol ñ 6 M ammo-
nia (4:1:2, v/v/v); the spots were densitometrically
recorded at λ = 298 nm (21).
Capillary electrophoresis with florescence
detection induced with laser for identification of
moxifloxacin in body fluids and capillary elec-
trophoresis with spectrophotometric detection in the
UV range for studies of enantiomeric purity (22, 23)
should be mentioned among other separation meth-
ods. Besides separation methods, differential pulse
polarography (24), differential pulse voltammetry
(25) and spectrophotometry (20, 26) or spectrofluo-
rimetry (27, 28) are applied for identification of
moxifloxacin.
There are not so many available papers on stud-
ies of acidic hydrolysis of moxifloxacin. Two publi-
cations report the acidic hydrolysis carried out using
0.5 M HCl at 50OC for 5 days; no presence of decom-
position products was observed (15). Djurdjevic et
al. demonstrated around 0.3% decomposition and
they detected two decomposition products in 0.1 M
HCl solution after 3 h heating at 50OC (16). 
After 10 h heating in 2 M HCl at 100OC, Salem
et al. demonstrated the presence of one decomposi-
tion product that was identified by infrared spec-
troscopy as a product of moxifloxacin decarboxyla-
tion (20). 
During stress studies with moxifloxacin,
Motwani et al. observed significant decomposition
of the compound after 3 h of heating at 40OC to 90OC
in 1 M HCl; however, they did not identified
decomposition products (21). 
Developent of chromatographic-densitometric
method for determination of stability of moxi-
floxacin in acidic solutions and the influence of
Cu(II), Fe(III), Zn(II) and Al(III) ions on kinetic (k,
t0.1, t0.5) and thermodynamic (Ea) parameters was the
aim of this study. In addition, LC-MS and 1H NMR
was used to determine the structure of hydrolysis
products.
EXPERIMENTAL
Chemicals and reagents
All reagents used for studies had analytical
quality and were manufactured by POCH Gliwice,
Poland or Merck, Darmstadt, Germany.
Standard substances
Moxifloxacin hydrochloride series Strasbourg
Cedex; Code:Y0000703; Id:002IC0; Council of
Europe ñ EDQM CS; Cat No. T30026 F-6081.
Apparatus 
● Densitometer ñTLC Scanner 3 with WinCats
1.3.4 software (Camag, Muttenz, Switzerland). 
● Sample applicator ñ Linomat V Camag (Muttenz,
Switzerland).
● TLC plates ñ 10 ◊ 12 cm (cut from 20 ◊ 20 cm
precoated TLC sheets of silica gel 60 F254 on alu-
minium; Art. 1.05548; Merck Darmstadt,
Germany).
● Chromatographic chamber ñ 17.5 ◊ 16 ◊ 8.2 cm
in size (Sigma ñ Aldrich, Cat. No. Z20, 415-3).
● Agilent 1100 LC system (Agilent Technologies,
Waldbronn, Germany).
● Column ñ XBridge C18 (30 ◊ 2.1 mm, 3.5 mm,
Waters, Ireland).
● Mass spectrometer: Applied Biosystem MDS
Sciex (Concord, Ontario, Canada) API 2000 triple
quadrupole mass spectrometer equipped with an
electrospray ionization ESI interface.
● NMR spectrophotometer: Mercury VX 300 MHz;
Varian (USA).
Solutions
Metal salts solutions. 
To prepare the solutions of metal ions at 0.1
mol/L concentration the following salts were used:
(1.2488 g) CuSO4 ◊ 5 H2O, (1.4337 g) ZnSO4 ◊ 7
H2O, (0.9988 g) Fe2(SO4)3 ◊ H2O, (1.6753 g)
Al2(SO4)3 ◊ 18 H2O. Above given weighed portions
of salts were transferred to 50 mL flasks and filled
with water to required volume. Directly for testing,
the obtained solutions were diluted with the same
solvent to a final concentration of 0.025 mol/ L.
Standard solution 
The amount of 0.2 g of moxifloxacin, weight-
ed with a precision of 0.1 mg, was dissolved in the
volume of 50 mL of methanol, and filled up to the
100 mL with the same solvent. For method valida-
tion, a solution with concentration of 60 µg/mL was
prepared, and later correspondingly diluted. 
Preparation of samples
The amount of 3.0 mL of 0.2% methanol solu-
tion of moxifloxacin, 3.0 mL HCl (3 mol/L) solution
and 1.0 mL of distilled water or solution with prop-
er salt with 0.025 mol/L concentration of metal ion
was added to 8.0 mL vials. Final concentration of
HCl in the studied samples was 1.3 mol/L. The vials
were tightly closed with plastic caps and placed in
incubator at temperatures 90OC and 110OC to pre-
vent them from direct light. The amount of 0.5 mL
of solution diluted with methanol to the final volume
of 10.0 mL was collected after 24, 48 and 72 h for
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further analysis. In case of occurrence of sediment,
the solutions were centrifuged at 3000 ◊ g for 10
min and supernatant was analyzed.
TLC analysis 
TLC conditions
A chromatographic-densitometric method was
used for identification of moxifloxacin and its
hydrolysis products. The amounts of 10 µL of solu-
tions were applied by Linomat V in a form of 8 mm
bands on TLC plates of 10 ◊ 12 cm in size. The
chromatograms of the height of 11.5 cm were devel-
oped by using mobile phase: methylene chloride ñ
ethanol ñ toluene ñ n-butanol ñ ammonia 25% ñ
water (6 : 6 : 2 : 3 : 1.8 : 0.3, v/v/v/v/v), then dried
at room temperature for 30 min. The peak areas
were scanned and recorded at λ ≈ 294 nm. The
absorption spectra within the range from 200 nm to
400 nm were recorded for identification purposes.
Identification of constituents was based on compar-
ison of retardation factor (Rf ) values and the absorp-
tion spectra. The percentage share of the constituent
(%i) was calculated from ratio of peak area of eval-
uated constituent (Ai) to the sum of all peak areas
(ΣA) on densitogram according to the formula %i =
(Ai/ΣA) ◊ 100. 
The study results represent average values
obtained from two measurements.
Method validation
The method was validated for specificity, lin-
earity, precision, recovery, limit of detection and
limit of quantitation according to ICH guidelines
(28). The specificity of the method is its ability to
measure analyte response in the presence of poten-
tial impurities. In order to determine the specificity,
20 µL of moxifloxacin solutions without and with
ions of studied metals, after hydrolysis were spotted
onto TLC plates. For linearity studies, aliquots of
0.03 µg per band to 2.5 µg per band of standard solu-
tions were applied on a TLC plate. Further analyti-
cal procedure was as described above.
Determination of linearity was made in three repli-
cates. Linearity was assessed as a relationship
between the mean peak area and concentration from
0.06 to 1.5 µg per band. Linearity was reported as
the linear calibration equations and the correlation
coefficients (r). For precision, repeatability of sam-
ple application and determination of peak area were
asessed by making 5 replicates of different amounts
of standard solution (0.12, 0.6, 1.2 µg per band).
Assay accuracy was determined by estimating
recovery percentage for moxifloxacin. Known
amount of standard substance of moxifloxacin
(80%, 100%, 120%) were added to model solution
of this compound. Recovery in percentage value
was calculated on the basis of determined content of
moxifloxacin to weighed amount. Each level was
analyzed in triplicate and a mean value from 9
analyses was taken as a result. In order to assess
limit of detection (LOD) and limit of quantitation
(LOQ) decreasing volumes (5, 4, 3, 2, 1 µg per
band) of standard solution of the concentration 6 µg
/mL were applied on a TLC sheet. Further analytical
procedure was as described above. Peak area was
measured and signal to noise ratio 3 : 1 was regard-
ed as LOD, whereas signal to noise ratio 10:1 was
regarded as LOQ.
LC/MS/MS analysis
High-performance liquid chromatography condi-
tions
Liquid chromatography was performed using
an Agilent 1100 HPLC system consisting of
degasser, a gradient pump, an autosampler and a
DAD detector. Chromatographic separation was
carried out with a commercially available XBridge
C18 column set at 30OC.
The mobile phase consisted of acetonitrile and
water with an addition of 0.01% formic acid was set
at a flow rate of 0.6 mL/min using a gradient elution.
Two solvent mixtures were used. Solvent A: ace-
tonitrile ñ formic acid (0.01%) and solvent B: water
ñ formic acid (0.01%). The following gradient was
used: 0ñ5 min, 0ñ100% A; 5ñ7 min, 100% A; 7ñ8
min, 100ñ0% A; 8ñ15 min, 100% B. A sample vol-
ume of 20 µL was injected onto the analytical col-
umn for compound analysis. 
Mass spectrometry conditions
Mass spectrometric detection was performed
on an Applied Biosystems MDS Sciex API 2000
triple quadrupole mass spectrometer equipped with
an electrospray ionization (ESI) interface and per-
formed in the positive ion mode. The mass scanning
was done on quadrupole Q1 in full scan mass spec-
trum using the mass range from m/z 50 to 1000 amu. 
A standard solution of polypropylene glycols
was used for instrument tuning and mass calibration
according to the Applied Biosystems manual. The
mass spectrometer was operated with a dwell time of
200 ms, and a 5 ms delay between scans for each tran-
sition in full scan mass spectrum on quadrupole Q1. 
To find the optimal parameters of the ion
source and the ion path, the mass spectrometer was
tuned by direct infusion of studied drug at a concen-
tration of 10 ng/mL using a Hamilton syringe pump
set at 5 µL/min.
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The ion source parameters were as follows: ion
spray voltage (IS): 5500 V; nebulizer gas (gas 1): 40
psi; turbo gas (gas 2): 45 psi; temperature of the
heated nebulizer (TEM): 300OC, and curtain gas
(CUR): 10 psi. Nitrogen (99.9%) from Peak
NM20ZA was used as the curtain and collision gas. 
The ion path parameters for moxifloxacin were as
follows: declustering potential (DP): 10V; focusing
potential (FP): 350V; entrance potential (EP): 10V,
electron multiplier (CEM): 2850V. Data acquisition
and processing were accomplished using the
Applied Biosystems Analyst version 1.4.2 software. 
1
H NMR analysis
Preparing samples for 1H NMR analysis
To identify the degradation products by 1H
NMR it was necessary to isolate individual con-
stituents from the chromatograms. For this purpose,
having developed chromatograms and after location
of bands of degradation products, appropriate layers
of gel were scraped off. The silica gel was shaken
mechanically with 5.0 mL methanol for 1 h, and
then filtered through a C8 column (Bakerbond speTM,
J.T. Baker, Denver, Holland). The solvent was
removed by distillation until a dry mass was
obtained. 
1H NMR conditions
NMR spectra were measured in mixture of
CDCl3 and CD3OD on a Varian Mercury-VX 300
spectrometer operating at 300.08 MHz (1H) and
282.32 MHz (19F), chemical shifts (δ in ppm) were
referenced to solvent lock signal. All spectra were
acquired at ambient temperature. Due to low sample
concentration, for each 1H NMR spectra 256 scans
were accumulated with spectral width of 4.2 kHz
and 16 k data points. 19F spectrum was recorded with
spectral width of 56 kHz and 64 k data points; 512
scans were accumulated for 19F spectrum acquisi-
tion.
RESULTS AND DISCUSSION
TLC analysis 
Well-developed peaks and good separation of
moxifloxacin from hydrolyze products were
Figure 1. The densitogram of moxifloxacin solution in hydrochloric acid in the absence of metal ions: A ñ before heating, B ñ after heat-
ing at 90OC for 72 h. Peak 1 ñ the degradation product.
Figure 2. Densitograms of moxifloxacin hydrolysis in the presence of metal ions: Fe(III) (A), Cu(II) (B) after 72 h heating at 90OC. Peak
1 ñ degradation product P-2
1
1
1
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obtained in the developed chromatographic condi-
tions. Retardation factors were Rf ≈ 0.32 for moxi-
floxacin and 0.15, 0.29 and 0.89 for degradation
products. Mobile phase: methylene chloride ñ
ethanol ñ toluene ñ n-butanol ñ ammonia 25% ñ
water (6 : 6: 2 : 3 : 1.8 : 0.3 v/v/v/v/v) used in these
studies for determination of moxifloxacin differs
from described in searched literature (20, 21). The
method was validated according to ICH require-
ments (29). 
Figure 3. Absorption spectra of moxifloxacin (MOXI) and its degradation product P-2 (1) after incubation for 72 h at 90OC
Figure 4. Densitograms of moxifloxacin hydrolysis in the absence (A) and in the presence of metal ions: Cu(II) (B) and Fe(III) (C) after
24 h heating at 110OC. Peaks: 1, 2, 3 = the degradation products: P-1, P-2, P-3
1
2
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1
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In the established method conditions, no mutu-
al peak interference, or influence of other con-
stituents present in the samples, was observed.
Therefore, it is considered that the developed
method meets the specificity criteria. The method is
characterized by a wide linear range, from 0.06 µg
per band to 1.5 µg per band, with good correlation (r
= 0.9900). The regression coefficient is P = 9354.5c
+ 2766.4, and the standard estimation error equals Se
= 808.2. This method has high sensitivity with LOD
= 12 ng per band and LOQ = 30 ng per band. Good
precision and intermediate precision RSD does not
exceed 1.08% and the recovery was from 100.34%
to 101.50%.
Figure 5. The ln c = f(t) graph of moxifloxacin in 3 mol/L hydrochloric acid at temperature 90OC
Figure 6. The ln c = f(t) graph of moxifloxacin in 3 mol/L hydrochloric acid at temperature 110OC
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Acidic hydrolysis of moxifloxacin 
Stability studies of moxifloxacin in acidic
environment have been an element of many publica-
tions in which authors demonstrated the presence of
one decomposition product obtained in the process
of decarboxylation (20) or few decomposition prod-
ucts which structure has not been identified yet (16,
21). 
In the searched literature, there was a lack of
data concerning stability of moxifloxacin in the
presence of metal ions, which may result in some
type of interaction during compound application in
medical care. Acidic hydrolysis of fluoroquinolones
with the presence of metal ions has been subjected
of many studies; however, they only concerned
ciprofloxacin and norfloxacin (30). Moxifloxacin
differs from the above-mentioned fluoroquinolones
at positions 7 and 8, and this difference has an influ-
ence on physical-chemical properties and stability of
the compound (31ñ33).
During selection of metal ions for studies, we
based our decision on the presence of metal ions in
many, commonly used diet supplements (Cu(II),
Fe(III), Zn(II)) or alimentary tract coating agents
(Al(III)), which can be administered during therapy
with moxifloxacin.
In preliminary studies, no change was observed
in moxifloxacin solutions in the presence and
absence of metal ions before incubation at 90OC and
110OC was applied. There was only one peak repre-
senting studied compound with Rf ≈ 0.32 value on
recorded densitograms (Fig. 1A). 
Decomposition of moxifloxacin in the pres-
ence and absence of metal ions proceeds in solutions
not earlier than after 24 h of heating at 90OC. This
decomposition intensifies with the increase of heat-
ing time. After 72 h of heating, the decomposition
process of moxifloxacin solutions in the absence of
metal ions did not exceed 10%. On the other hand,
the decomposition process was much faster in the
presence of metal ions: Cu(II) 41.92%, Fe(III)
13.61%, Zn(II) 12.8% and Al(III) 11.25%.
Besides moxifloxacin peak with Rf ≈ 0.32
value, only one extra peak (P-2) with Rf ≈ 0.29 value
Figure 7. HPLC chromatogram with diode array detection of studied sample of moxifloxacin in acidic conditions with addition of cuprum
ions (A), mass spectrum of sample of studied drug at retention time of 2.65 min (B), 2.85 min (C), 2.97 min (D) and 3.4 min (E), respec-
tively
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occurred on all the recorded chromatograms. (Fig.
1B and 2).
The absorption spectra directly recorded from
chromatograms within the range from 200 to 400
nm for spot coming from decomposition product (Rf
≈ 0.29) had similar shape and their maximum was
slightly shifted in a direction of shorter wavelengths
(λmax ≈ 288 nm) in relation to spectra of moxi-
floxacin (λmax ≈ 295 nm) (Fig. 3). 
Based on these observations, it may be
assumed that the same decomposition product with
structure similar to moxifloxacin is generated inde-
pendently on the composition of study solutions.
Higher decomposition of moxifloxacin was
demonstrated during studies performed at 110OC.
This decomposition was 52.04% after 48 h and
increased in the presence of metal ions: Cu(II)
(79.35%), Fe(III) (63.97%), Al(III) (62.42%) and
Zn(II) (58.62%). The observed changes of moxi-
floxacin in the presence and absence of metal ions
are similar to changes at 90OC. The highest decom-
position was observed in the presence of Cu(II) ions,
and slower in case of Fe(III) to Zn(II) ions. 
Besides increased decomposition of moxi-
floxacin, the observed changes also concern the
number of generated decomposition products.
Similar to studies at 90OC, a (P-2) peak with Rf ≈
0.29 value and two extra peaks (P-1) and (P-3) with
Rf ≈ 0.15 and Rf ≈ 0.89 values, respectively, were
observed next to the studied compound on densi-
tograms independently of the composition of the
solution (Fig. 4).
The maxima of absorption spectra for decom-
position products differ between themselves, P-1 (λ1
≈ 275), P-2 (λmax ≈ 288 nm), P-3 (λmax1 ≈ 281), and
are slightly shifted towards shorter wavelengths in
comparison to parent compound (λmax ≈ 295 nm). In
case of P-3 product, a well developed maximum of
absorption at λ ≈ 340 nm is observed. Therefore, the
structure of quinolinic ring is probably maintained
and observable differences are only related to suit-
able substituents.
Kinetic and thermodynamic evaluation 
For kinetic evaluation, results of moxifloxacin
decomposition at 90OC and 110OC were taken for
consideration. It was established that decomposition
of moxifloxacin in solutions in the presence and
absence of metal ions proceeds according to kinetics
of the first-order reaction based on changes of ln c =
f(t) (Figs. 5 and 6).
The constant rate (k) for study solutions con-
taining metal ions decreases in the following order:
Cu(II) > Fe(III) > Zn(II) > Al(III), reaching the low-
est value for moxifloxacin solutions in the absence
of metal ions. The calculated values of t0.1 and t0.5
confirm better stability of moxifloxacin in solutions
in the absence of metal ions, and the stability
decreases in the presence of Zn(II), Al(III), Fe(III)
ions and reaching the lowest stability in the presence
of Cu(II) ions (Tab. 1).
The calculated energy activation (Ea) value for
hydrolysis process of mixofloxacin solutions in the
presence of Cu(II) (Ea = 85.83 kJ/mol) is lower than
values both obtained in the presence of Fe(III) (Ea =
138.42 kJ/mol), Al(III) (Ea = 138.52 kJ/mol) and
Zn(II) Ea = 141.82 kJ/mol), and in the absence of
metal ions (Ea Moxi = 141.92 kJ/mol). 
Table 1. The kinetic results of moxifloxacin decomposition in the presence and absence of metal ions at temperature 90OC and 110OC.
Temperature Rate t0.1 t0.5 Correlation
[OC] Ion  constant [h] [h] coefficient
k ◊ 10-2 [h-1] 
Cu(II) 0.74 14.23 93.65 0.9312
Fe(III) 0.19 55.42 364.74 0.9769
90 Al(III) 0.18 59.76 393.30 0.9478
Zn(II) 0.18 59.93 394.42 0.9645
None 0.16 65.81 433.13 0.9777
Cu(II) 3.27 3.22 21.19 0.9998
Fe(III) 2.16 4.88 32.08 0.9994
110 Al(III) 2.10 5.01 33.00 0.9981
Zn(II) 1.98 5.32 35.00 0.9831
None 1.54 6.84 45.00 0.9998
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Based on the individual results of Ea and t0.1
and t0.5 parameters, some type of similarity may be
observed, namely, both kinetic as well as thermody-
namic parameters differ significantly in
mixofloxacin solutions in the presence of Cu(II)
ions, in which the strongest decomposition occurs,
from values obtained for other solutions.
It seems that the effect of ions on decomposi-
tion of mixofloxacin and their varied contribution to
the hydrolysis process, can be read as a complex-
generated activity of individual metal ions with
quinolones, which results in formation of less or
more solid bonds prone to decomposition. 
Identification of hydrolysis products 
LC-MS
The identification of degradation products of
moxifloxacin and their structural analysis was done by
LC-ESI/MS method. Three potential degradants were
identified using the above mentioned procedure. 
Figure 8. 1H NMR spectrum of degradation product P-3
Figure 9. 1H NMR spectrum of degradation product P-2
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Figure 7A illustrates the HPLC diode array
chromatogram of a sample of moxifloxacin under its
degradation process in acidic environment with addi-
tion of cuprum ions at temperature of 110OC. The
parent compound of moxifloxacin (m/z 402.6 amu)
was observed at retention time of 2.97 min (Fig. 7D). 
In the full scan mass spectrum of studied sam-
ple of moxifloxacin under the degradative analysis
we observed at a retention time of 2.65 min a possi-
ble degradative product with m/z 358.1 amu, due to
the loss of the functional carboxyl group from stud-
ied drug (Fig. 7B).
The next process could involve decarboxylation
and hydrolysis of 2,8-diazabicyclo[4.3.0]non-8-yl
group reaction of moxifloxacin which gives the final
product with m/z 263.4 amu observed at retention
time 3.4 min (Fig. 7E). The similar reaction could be
observed for degradation product at retention time of
2.85 min having m/z 249.7 amu (Fig. 7C).
1H NMR
1H NMR spectrum of sample P-3 shows char-
acteristic signals corresponding to chemical struc-
ture of degradation product (Fig. 8).
Figure 10. The plausible degradation patterns of moxifloxacin under studied conditions
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The most important are signals of quinoline
moiety protons, which indicate decarboxylation of
starting compound. Two doublets at δ 7.65 ppm (d,
J = 7.7 Hz, H2) and δ 5.98 ppm (d, J = 7.7 Hz, H3)
are clearly visible. The latter corresponds to proton
in the position of detached carboxylic group. In the
aromatic fragment of spectrum there is one more
doublet possessing large coupling constant: δ 7.53
ppm (d, J = 14.1 Hz, H5). This large value of cou-
pling constant corresponds to H-C-C-F system.
Confirmation can be found in 19F spectrum which
exhibits only one signal: δ ñ123.58 ppm (d, J = 14.7
Hz) indicating fluorine atom coupled with one pro-
ton. Despite of complicated pattern of signals
observed in the aliphatic region of spectrum it is
possible to conclude that there are no other changes
in chemical structure of analyzed compound.
Signals in the range 4ñ1 ppm can be assigned to pro-
tons of 2,8-diazabicyclo[4.3.0]nonane moiety and
signals between 1 and 0.5 ppm can be assigned to
protons of cyclopropyl fragment. There is also visi-
ble strong singlet at δ 3.41 ppm corresponding to
protons of methoxyl group. Analysis of P-3 spec-
trum clearly indicates that on this stage of degrada-
tion process only decarboxylation occurs, while the
rest of molecule remains unchanged.
Due to very low concentration of investigated
compound P-2, analysis of its spectrum is possible
only through the comparison to spectrum of sample
P-3. It is worth to note that in aromatic range of spec-
trum similar pattern of signal is observed (Fig. 9). 
Three doublets at δ 7.65, 7.53 and 6.14 ppm
indicate the same manner of substitution of quino-
line moiety, which confirms decarboxylation
process. Quite different set of signals observed in
the aliphatic region of spectrum shows that degrada-
tion of bicyclic fragment occurs. Singlet at δ 3.38
ppm can be assigned to protons of methyl group
yielded from this process. Apart of that changes, it is
possible to find singlet assigned to methoxyl group
protons at δ 3.41 ppm, indicating that hydrolysis
process in this fragment of the starting compound
does not occur. On that basis it can be assumed that
sample P-2 contains the product of subsequent
decarboxylation and degradation of diazabicyclic
moiety, which can be treated as a next step of mox-
ifloxacin degradation.
The structure for P-1 spot could not be fully
confirmed by 1H NMR technique because of the low
amount of received product and strong interferential
background coming from the gel. However, based
on the LC-MS results it may be assumed that the
compound with  m/z = 249.6 amu (P-1 spot) has a
structure presented on Figure 10.
CONCLUSION
In this paper, a new method for determination
of moxifloxacin beside hydrolysis products was
developed. This method allows evaluation of
hydrolysis process in the acidic environment in the
studied concentration ranges. It was proved that sta-
bility of moxifloxacin depends on temperature, heat-
ing time, and the presence of metal ions in solution. 
The highest impact on decomposition of moxi-
floxacin have Cu(II) ions. This impact decreases in
the following order Fe(III) > Al(III) > Zn(II). 
Decomposition of moxifloxacin in the pres-
ence of metal ions proceeds according to the kinet-
ics of the first-order reaction. The presence of metal
ions in moxifloxacin solutions increases the rate of
the reaction (k) and decreases activation energy (Ea),
which is well exemplified in the case of Cu(II) ions.
In the remaining solutions, independent on their
composition, changes in the above parameters are
not significant. 
Based on the calculated t0.1 and t0.5 values, it
can be assumed that decomposition of moxifloxacin
is faster in the presence of ions. Under described
conditions, decomposition process of moxifloxacin
results in development of three degradation prod-
ucts, which structures were determined by LC-MS
and 1H NMR techniques (Fig. 10).
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